Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KPT-330-modulated cold adaptation in various thermogenic organs of prediabetic mice

ABSTRACT: Transcriptomic analysis on white adipose tissues (WAT), brown adipose tissues (BAT), skeletal muscles and liver from cold-exposed obese mice treated with KPT-330 or DMSO, and those from obese mice housed at ambient temperature indicated that KPT-330 profoundly modulates immune responses in these thermogenic tissues and organs.

ORGANISM(S): Mus musculus

PROVIDER: GSE246327 | GEO | 2024/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

XPO1 blockade with KPT-330 promotes apoptosis in Cutaneous T- cell Lymphoma by activating the p53-p21 and p27 pathways

Project description:To assess the effects of XPO1 inhibition with small molecule inhibitor KPT-330 on Cutaneous T-cell Lymphoma after 48 hours of treatment

2024-04-23 | GSE262491 | GEO

RNA sequencing of patient-derived AML xenografts treated with Selinexor (KPT-330)

Project description:RNA sequencing of patient-derived AML xenografts treated with Selinexor (KPT-330)

| PRJNA820015 | ENA

Analysis of gene expression changes in KPT330-treated HMLE cells transduced to stably overexpress SNAI1

Project description:HMLE-SNAIL cell cultures were treated with KPT330 drug (KPT, 150 nanomolar) or vehicle (DMSO) for 24 hours, in parallel quadruplicates. KPT-330 is an Exportin 1 (XPO1) inhibitor with possible pluripotent or unexpected effects on cell signaling. Total RNA was isolated and analyzed in an Agilent two-color experiment, where four biological replicates of each condition were directly compared, expression ratios are KPT-treated condition relative to control (DMSO vehicle-treated) The experiment object was to identify genes that displayed significantly altered expression in response to KPT treatment inorder to confirm on-target drug impact and elucidate other potential effects in this cell line model.

2015-08-31 | E-GEOD-69326 | biostudies-arrayexpress

Analysis of gene expression changes in KPT-185-treated HMLE cells transduced to stably overexpress SNAI1

Project description:HMLE-SNAIL cell cultures were treated with KPT-185 drug (KPT, 150 nanomolar) or vehicle (DMSO) for 24 hours, in parallel quadruplicates. KPT-185 is an Exportin 1 (XPO1) inhibitor with possible pluripotent or unexpected effects on cell signaling. Total RNA was isolated and analyzed in an Agilent two-color experiment, where four biological replicates of each condition were directly compared, expression ratios are KPT-treated condition relative to control (DMSO vehicle-treated).

2015-08-31 | GSE69326 | GEO

RNASeq analysis of calcification stages (and KPT) in pAVICs

Project description:In order to assess transcriptome profile of different calcification stages and KPT, RNA-Seq analysis was performed

2018-12-15 | GSE114726 | GEO

Tulasnella sp. 330

Project description:Tulasnella sp. 330 Resequencing genome sequencing

| PRJNA557739 | ENA

The XPO1 inhibitor KPT-8602 synergizes with dexamethasone for the inhibition of acute lymphoblastic leukemia

Project description:Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Survival of ALL patients has improved significantly over the last 50 years. However, the current intensified chemotherapy is associated with serious short and long-term side effects in these young patients. Whereas KPT-8602 is a second generation exportin-1 (XPO-1) inhibitor with potent activity against ALL in pre-clinical models and with minimal effects on normal cells. In this study, we evaluated if synergistic ALL inhibition could be obtained by combining KPT-8602 with dexamethasone, vincristine or doxorubicin. Combination of KPT-8602 with dexamethasone showed the strongest synergistic effect on human B-ALL and T-ALL cell lines. This synergy was confirmed in vivo on three patient-derived ALL xenografts. Compared to single drug treatment, the drug combination caused increased apoptosis, reduced cell cycle gene expression and led to histone depletion. mRNA expression analysis and ChIP-seq revealed that addition of KPT-8602 to dexamethasone increased transcript level and binding of the glucocorticoid receptor, as well as NFKBIA expression. Dexamethasone concentrations could be reduced 5 to 10-fold in the presence of KPT-8602 to achieve the same level of NFKBIA induction as with dexamethasone alone. Our pre-clinical study demonstrates that combination of KPT-8602 and dexamethasone is highly synergistic in vivo. This opens the possibility to reduce dexamethasone concentrations and reduce side effects in future clinical trials.

2019-08-05 | GSE135350 | GEO

KPT-330 has antitumour activity against non-small cell lung cancer.

Project description: Not available

| S-EPMC4102938 | biostudies-literature

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

Project description: Not available

| S-EPMC5352339 | biostudies-literature

Pseudomonas sp. S06B 330

Project description:Pseudomonas sp. S06B 330 Genome sequencing

| PRJNA422266 | ENA